BRCA2 and ovarian carcinoma: In Finland, strong founder effects and enrichment of deleterious alleles are seen [4] and major founder mutations in BRCA1 and BRCA2 [5] as well as in other breast and ovarian cancer susceptibility genes account for the vast majority of the identified mutations.